Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 DYN101 trial in centronuclear myopathies due to DNM2 or MTM1 mutations
NL-OMON52921Phase 2Completed
- Sponsor
- Dynacure
- Start
- Feb 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of DYN101 in centronuclear myopathy (CNM) (2 arms), sponsored by Dynacure. Primary endpoint: Safety and tolerability of single and multiple ascending doses of DYN101. Started Feb 2020; status: completed.
02
Drugs
DYN101
03
Conditions
centronuclear myopathy (CNM)
Beyond the preview
Go deeper on NL-OMON52921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52921.